Farah Madhani-Lovely, MD
Critical Care Medicine · Reno, NVNPI 1821112848
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 76.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $10,943 and has fallen 89.3% since, to $1,175 in 2025. Among critical care medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $219.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- Boehringer Ingelheim$1K
- Medical Device Business Services, Inc.$980
- Genentech, Inc.$155
- Olympus Corporation Of The Americas$153
- Inari Medical, Inc.$147
- plus $1K from 13 others
Across 227 payments — averaging $6130.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$480K
- Boehringer Ingelheim$322K
- Genentech, Inc.$229K
- GSK$162K
- Hoffmann-la Roche Limited$62K
- United Therapeutics Corporation$59K
- plus $77K from 4 others
What the payments were for
- Travel & lodging$4,08727%
- Food & beverage$2,06713%
- Education$9,19260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 33 | $11,760 |
| Boehringer Ingelheim | 3 | $1,078 |
| Medical Device Business Services, Inc. | 4 | $980 |
| Genentech, Inc. | 3 | $155 |
| Olympus Corporation Of The Americas | 2 | $153 |
| Inari Medical, Inc. | 1 | $147 |
| Insmed, Inc. | 4 | $137 |
| Genentech USA, Inc. | 1 | $130 |
| Olympus America Inc. | 2 | $128 |
| Siemens Medical Solutions USA, Inc. | 1 | $125 |
| AstraZeneca | 1 | $117 |
| Inspire Medical Systems, Inc. | 2 | $91 |
| GSK | 5 | $86 |
| Novartis | 1 | $73 |
| United Therapeutics Corporation | 1 | $58 |
| Boston Scientific | 2 | $38 |
| Advanced Respiratory, Inc | 2 | $36 |
| ERBE USA Inc | 1 | $30 |
| Veran Medical Technologies, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- DAVINCI XI$3,000
- Da Vinci Surgical System$1,918
- MONARCH$947
- FLOWTRIEVER CATHETER, S$147
- CT THROMBECTOMY SYSTEM KIT$147
- Cios Spin$125
- SINGLE USE SUCTION VALVE (Sterile)$118
- TAGRISSO$117
How this compares
$15,346 in reported general payments places this provider in the 95th percentile of 68 critical care medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,719 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,247 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $3,355 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $2,911 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $485 |
| Ethambutol Hcl | 13 | $399 |
| Mycophenolate Mofetil | 12 | $320 |
| Rifampin | 13 | $259 |
| Azithromycin | 16 | $140 |
| Prednisone | 21 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $86 | $20,96628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 critical care medicine providers in Nevada.
Other critical care medicine in Reno
- Hannah LeitchReno$8K
- Jeffrey BaconReno$5K
- Fernando FuentesReno$4K
- Faisal SiddiquiReno$2K
- Joshua BiglerReno$674
- Rudy TedjaReno$587
- Jeremy GondaReno$531
- Jason BlockReno$462
- Joshua JewellReno$399
- Richard MaierReno$312
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.